Tag Archives: family offices

Hot Investor Mandate 1: Family Office Creates Investment Arm for Medical Device Companies Based in the U.S.

10 May

A family office arm specializes in investing in and operating medical device companies in which it holds a controlling interest. The firm looks to invest in early and seed stage companies with the goal of investing in 1-2 companies per year to add to its portfolio.

The firm looks to invest in medical device companies that are still in development. The firm prefers technologies subject to the FDA 510(k) pathway, but will consider PMA/combination device and therapeutics if the technology is extremely disruptive. The investors are agnostic with regards to subsector and indication. Current portfolio companies include surgical tools for cardiovascular interventions, consumer health electronics, hospital hardware and therapeutic delivery devices for multiple clinical applications.

The firm looks to invest in companies with great technology that need operational expertise to help advance the technology to market with the goal of leveraging its internal management team for execution of product development, regulatory, and commercial strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: China-Based Family Office Seeks Global Investment and In-Licensing Opportunities with Focus in USA & UK

26 Apr

A venture capital fund/family office based in Hangzhou, China currently manages two venture funds in addition to a number of private capital accounts through which investments are made – these two funds focus on life sciences. The firm primarily makes equity investments in early-stage rounds ranging from $1 million initially; for later-stage to pre-IPO companies, the firm looks to make initial equity investments ranging from $3-5 million. The firm looks for companies located around the globe, with a preference in the US and Europe (UK). Currently, the firm is also actively seeking in-licensing opportunities in biotech innovations that has a China angle. The firm is actively looking for investment opportunities.

The firm is a flexible and opportunistic investor and will consider therapeutics, medical devices, and diagnostics. The firm is open to all kinds of sectors and indications. For therapeutics, the firm has specific focuses on novel candidates for disease, PD1-base approaches, gene therapy, oncology, cardiovascular diseases, and small molecules. For medical devices, the firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is also interested in diagnostics although this area is less of a focus. In terms of therapeutics, the firm will look at products of pre-clinical stage and later stages from phase II to phase III. Regarding medical devices, the firm will invest at any stage of development.

The firm is looking for private companies only. The firm typically has no specific requirements for the management team, but this depends on how much the firm invests. The firm looks to take a board seat following the investment and is comfortable acting as both a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Meet the Family Office Panelists at RESI Toronto

5 Apr

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

For every RESI event, the LSN Investor Research team aims to recruit a diverse slate of panels with experienced investors of all types and focus areas within life science technology. As one of the more highly sought types of investors for entrepreneurs, Family Offices is a recurring panel at RESI. Mostly backed by private wealth as evergreen funds, family offices often have deep connections in the life science field both professionally and, at times, personally—some family office investors have loved ones battling debilitating diseases. Family offices are highly idiosyncratic with their own motivations and strategies, though despite their differences and founding stories, they continue to play actively within life science investment.

On April 10th at RESI Toronto, we will hear from four family offices that invest in several different life science sectors. Moderated by Catherine Love, Director of Capital Services for MaRS Discovery District, the panelists include:

  • Sherry Grisewood, Chief Investment Office, Foxhill Asset Management
  • David Ramos, CFO, AGP Holdings
  • Chuck Stetson, CEO, Stetson Family Office
  • Oded Levi, President, Epstein Enterprises

Register now for RESI Toronto at the MaRS Discovery District on April 10th to hear from these experienced individuals.

RESI San Diego: Family Office Investors Discuss Strategy and What Makes Them Different

20 Jul

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

As the RESI San Diego event is now in the rearview mirror and we prepare to bring RESI home to Boston (Sept. 26th), we wanted to take a closer look at the Medtech Family Office panel session. Family offices are clearly a highly sought-after investor class and are not completely understood by a large portion of entrepreneurs. To that end, we’ve pulled out some of the most insightful points that were discussed and distilled the panel session into this summary video to help shed some light on how family offices evaluate early-stage investments, how to reach them and what differentiates them from VCs and other early-stage investors.

Family offices are not a silver bullet for your financing needs

A lot of entrepreneurs mistakenly believe that finding a family office will solve all their fundraising woes i.e. long-term investors with less rigid requirements. While it is true that family offices tend to be more patient capital and more flexible with terms and deal structures (a result of not having to answer to LPs), these groups are in fact looking for a return and typically will be active either at the board or management level to hit milestones and create value. Additionally, as your company grows and matures, the capital requirements and expertise required for the healthcare space oftentimes necessitate bringing in deep-pocketed institutional investors, who family offices maintain relationships with.

Family offices are purposefully low visibility

Given that family office investors have no mandate or timeline to allocate money, they can wait on the best deals and entrepreneurs to surface, therefore their deal sourcing channels are much different than a VC or another institutional investor. Further, these groups tend to be very much relationship-oriented. Networking is a must to uncover these investors and begin building a relationship, with some of the best events to attend being a part of universities and tech transfer offices as well as focused partnering conferences, such as the RESI conference.

Family offices are not homogenous

This point can’t be stressed enough. While there are some common themes among these groups (mostly dictated by structure or lack thereof), they are largely very different. Some may be more philanthropically motivated as they are looking to fund research/companies pursuing indications that have afflicted their family while others act more like an institutional fund with a focus on returns. It is essential to do as much research as possible on each specific family office to try and find mutual connections and the best way to approach them.

Moderated by Michael Quigley, VP of Investor Research, LSN, the panel includes the following speakers:

  • Sean Kearny, Managing Director, Three Leaf Ventures
  • Kyle Williams, President, Bootstrap Incubation
  • John Kinzell, Sr. Life Science Analyst, The McNair Group
  • Julia Belaya, Director – Corporate Partnerships, Plug & Play Tech Center

Must See Video—CEOs explain sourcing Family Offices, Working Your Pipeline and Cost of Campaigns – Tales from the Road at RESI

13 Jul

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

More frequently than not LSN captures content through its RESI panels that hits the nail on the head. The recent “Tales from the Road” Panel does just that. It’s 6 minutes long but worth a viewing it if you are a scientist-entrepreneur or fundraising CEO. The most vital take-aways include how to source potential investors (particularly family offices), the process of “working” your pipeline of investors, and the costs associated with conducting a successful campaign.

The panel brought together successful biotech and medtech entrepreneurs to tell their stories of successfully raising capital. These are seasoned entrepreneurs who have been there done that and collectively have raised numerous private financing rounds and have exited multiple companies, with combined total deals exceeding $750 MM. They came to RESI San Diego to share their wisdom to fellow fundraising executives and provide insight in order to help their peers succeed.

Family Offices Converge on RESI to Meet Early Stage Biotech and Medtech Startups

8 Jun

By Lucy Parkinson, Director of Research, LSN

RESI is a venue where early stage life science startups can meet with investors of every type that are a fit for their company’s technology and stage – and that includes family offices. RESI San Diego features two panels devoted to this elusive investor class – Biotech Family Offices and Medtech Family Offices. Whether you’re developing a novel therapeutic, an innovative device or an improved diagnostic solution, Family Offices can’t be overlooked as a potential source of capital and RESI will provide you with the opportunity to hear advice and insight directly from key investment decision makers from family offices.

Biotech Family Offices, moderated by Colin Widen (CEO, Boston Innovation Capital), features:

Medtech Family Offices, moderated by Michael Quigley (VP of Market Research, Life Science Nation), features:

To catch this rare opportunity to meet family office investors with a focus on early stage life science investment, register for RESI now.

RESI San Francisco Panel Announcement: Biotech Family Offices

15 Dec

By Lucy Parkinson, Director of Research, LSN

RESI has always aimed to represent the diversity of capital sources for early stage life science companies; alongside sessions featuring VCs, pharma, angels, and other traditional sources of capital, LSN is proud to feature two sessions devoted to Family Offices that invest in new healthcare ventures. The Biotech Family Office sesssion features investors from five different firms who will cover the wide-ranging interests of family offices in the early stage drug development sector.

Moderated by Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital), the panelists are:

Christine Bunt (Venture Partner, 20/20 HealthCare Partners)
Will Eden (Vice President, Thiel Capital)
Daron Evans (Managing Director, PoC Capital)
Alex Pickett (Associate, Mediqventures)

If you’d be interested in hearing how these family offices source and assess biotech opportunities, and what you need to do to align your company with their investment ethos, you can register for RESI now.

resi-san-francisco-2017

%d bloggers like this: